Clinical stage biopharma company Rexahn Pharmaceuticals has entered into an exclusive licensing agreement with the University of Maryland, Baltimore (UMB), for a novel drug delivery platform, which targets the delivery of chemotherapeutic ...
Tags: Rexahn Pharma, Oncology Drug